Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases

Adolescents with underlying diseases are at risk of severe COVID-19. The immune response of BNT162b2 may be poor among immunocompromised adolescents. We aim to describe immunogenicity of mRNA BNT162b2 among adolescents who are immunocompromised or have chronic diseases. We recruited adolescents 12–18 years of age; group A impaired-immunity (post-transplantation, cancer, on immunosuppressive drugs) and group B chronic diseases. A two-dose regimen of BNT162b2 was given. Immunogenicity was determined by surrogate virus neutralization test (sVNT) and IgG against receptor-binding domain (RBD). From August to October 2021, 312 adolescents, with a median age (IQR) of 15 years (13.7–16.5), were enrolled (group A 100, group B 212). The geometric means (GMs) of sVNT (% inhibition) against Delta strain and anti-RBD IgG (BAU/mL) after the 2nd dose among group A were: post-transplantation recipients 52.9 (95% CI 37.7–74.2) and 233.6 (95% CI 79–690.6); adolescents with cancer 62.3 (95% CI 29.2–133.1) and 214.9(95% CI 34.2–1348.6); and adolescents with other immunosuppressive conditions 66.7 (95% CI 52.4–84.8) and 849.8 (95% CI 393.4–1835.8). In group B were: adolescents living with HIV 98 (95% CI 97.3–98.8) and 3240.3 (95% CI 2699–3890.2), and adolescents with other chronic disease 98.6 (95% CI 98.3–98.9) and 3818.5 (95% CI 3490.4–4177.4). At day 90, immunity declined; among impaired-immunity participants were 43.9 (95% CI 30.8–62.4) and 178.7 (95% CI 91.2–350.1) and adolescents with chronic diseases were 90.6 (95% CI 88.4–92.8) and 1037.1 (95% CI 933.3–1152.5). In conclusion, adolescents with impaired immunity had a poor response to 2-doses of BNT162b2, additional dose should be considered. Adolescents with chronic diseases had excellent response but immunity waned after 3 m, booster dose may be required.

[1]  G. Alter,et al.  Durability and cross-reactivity of SARS-CoV-2 mRNA vaccine in adolescent children , 2022, medRxiv.

[2]  G. Alter,et al.  Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals , 2021, The Journal of infectious diseases.

[3]  William F. Fadel,et al.  Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[4]  T. Puthanakit,et al.  Clinical outcomes of pediatric COVID-19 in a tertiary care center in Bangkok, Thailand , 2021, IJID Regions.

[5]  B. Bell,et al.  The Advisory Committee on Immunization Practices’ Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[6]  Robin L. Jones,et al.  Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study , 2021, Nature Cancer.

[7]  Y. Kreiss,et al.  Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months , 2021, The New England journal of medicine.

[8]  B. Salzberger,et al.  Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2 , 2021, Vaccines.

[9]  E. Ingulli,et al.  Immunologic response of mRNA SARS-CoV-2 vaccination in adolescent kidney transplant recipients , 2021, Pediatric Nephrology.

[10]  K. Syrigos,et al.  Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection , 2021, Vaccines.

[11]  Gregory F. Wu,et al.  Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 , 2021, Annals of Internal Medicine.

[12]  H. Samji,et al.  Review: Mental health impacts of the COVID‐19 pandemic on children and youth – a systematic review , 2021, Child and adolescent mental health.

[13]  C. Broder,et al.  Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers , 2021, medRxiv.

[14]  S. Fourati,et al.  Antibody response after second BNT162b2 dose in allogeneic HSCT recipients , 2021, The Lancet.

[15]  J. Vekemans,et al.  Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[16]  G. Shefer,et al.  Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study , 2021, Annals of the Rheumatic Diseases.

[17]  Manish M Patel,et al.  Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2 , 2021, JAMA network open.

[18]  P. Dormitzer,et al.  Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents , 2021, The New England journal of medicine.

[19]  D. Segev,et al.  High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases , 2021, Annals of the Rheumatic Diseases.

[20]  D. Segev,et al.  Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. , 2021, JAMA.

[21]  D. Yahav,et al.  Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study , 2021, Clinical Microbiology and Infection.

[22]  A. Huppert,et al.  Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1 , 2021, Clinical Microbiology and Infection.

[23]  D. Schwartz,et al.  Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus , 2021, American Journal of Transplantation.

[24]  S. Dominguez,et al.  Risk Factors for Severe COVID-19 in Children. , 2021, The Pediatric infectious disease journal.

[25]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[26]  P. Dormitzer,et al.  COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses , 2020, Nature.

[27]  Deblina Roy,et al.  Impact of COVID-19 and lockdown on mental health of children and adolescents: A narrative review with recommendations , 2020, Psychiatry Research.

[28]  M. Chen,et al.  A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction , 2020, Nature Biotechnology.

[29]  Ansel Hoang,et al.  COVID-19 in 7780 pediatric patients: A systematic review , 2020, EClinicalMedicine.